1079 |
FFR Clinical Trials and Applications: Make the PCI Practice Changed |
William F. Fearon |
May. 12. 11 |
1078 |
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery |
Martin Bert Leon |
May. 12. 11 |
1077 |
Long-Term Outcome of Open or Endovascular Repair of Abdominal Aortic Aneurysm (DREAM Trial) |
Philippe Cuypers |
May. 12. 11 |
1076 |
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: Meta-anlysis |
Marc S. Sabatine |
May. 12. 11 |
1075 |
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment |
Guillaume Pare |
May. 12. 11 |
1074 |
Sirolimus-Eluting Stent versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the J-Cypher Registry |
Takeshi Kimura |
May. 12. 11 |
1073 |
Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry |
Duk-Woo Park |
May. 12. 11 |
1072 |
Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents Observations From the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) |
Takeshi Kimura |
May. 12. 11 |
1071 |
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents |
Patrick W. Serruys |
May. 12. 11 |
1070 |
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV) |
Gregg W. Stone |
May. 12. 11 |